ATE430600T1 - 2-(3,5-bis-trifluormethyl-phenyl)-n- 6-(1,1-dio o-1.lambda.6-thiomorpholin-4-yl)-4-(2-methyl- oder 4-fluor-2-methyl-substituiertes)phenyl-pyridin- - yl -n-methyl-isobutyramid - Google Patents

2-(3,5-bis-trifluormethyl-phenyl)-n- 6-(1,1-dio o-1.lambda.6-thiomorpholin-4-yl)-4-(2-methyl- oder 4-fluor-2-methyl-substituiertes)phenyl-pyridin- - yl -n-methyl-isobutyramid

Info

Publication number
ATE430600T1
ATE430600T1 AT02791471T AT02791471T ATE430600T1 AT E430600 T1 ATE430600 T1 AT E430600T1 AT 02791471 T AT02791471 T AT 02791471T AT 02791471 T AT02791471 T AT 02791471T AT E430600 T1 ATE430600 T1 AT E430600T1
Authority
AT
Austria
Prior art keywords
methyl
phenyl
trifluormethyl
isobutyramide
dio
Prior art date
Application number
AT02791471T
Other languages
English (en)
Inventor
Theresa Ballard
Torsten Hoffmann
Sonia Poli
Patrick Schnider
Andrew Sleight
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE430600T1 publication Critical patent/ATE430600T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
AT02791471T 2001-07-31 2002-07-26 2-(3,5-bis-trifluormethyl-phenyl)-n- 6-(1,1-dio o-1.lambda.6-thiomorpholin-4-yl)-4-(2-methyl- oder 4-fluor-2-methyl-substituiertes)phenyl-pyridin- - yl -n-methyl-isobutyramid ATE430600T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01118412 2001-07-31
PCT/EP2002/008311 WO2003011860A2 (en) 2001-07-31 2002-07-26 2-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-N-[6-(1,1-DIOXO-1λ6-THIOMORPHOLIN-4-YL)-4-(2-METHYL OR 4-FLUORO-2-METHYL SUBSTITUTED)PHENYL-PYRIDIN-3-YL]-N-METHYL-ISOBUTYRAMIDE

Publications (1)

Publication Number Publication Date
ATE430600T1 true ATE430600T1 (de) 2009-05-15

Family

ID=8178193

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02791471T ATE430600T1 (de) 2001-07-31 2002-07-26 2-(3,5-bis-trifluormethyl-phenyl)-n- 6-(1,1-dio o-1.lambda.6-thiomorpholin-4-yl)-4-(2-methyl- oder 4-fluor-2-methyl-substituiertes)phenyl-pyridin- - yl -n-methyl-isobutyramid

Country Status (29)

Country Link
US (1) US6849624B2 (de)
EP (1) EP1414525B1 (de)
JP (1) JP4700908B2 (de)
KR (1) KR100577101B1 (de)
CN (1) CN1289497C (de)
AR (1) AR034921A1 (de)
AT (1) ATE430600T1 (de)
BR (1) BR0211523A (de)
CA (1) CA2452502C (de)
DE (1) DE60232246D1 (de)
EA (1) EA006238B1 (de)
EC (1) ECSP044963A (de)
ES (1) ES2324209T3 (de)
GT (1) GT200200159A (de)
HR (1) HRP20040039A2 (de)
HU (1) HUP0400398A3 (de)
MA (1) MA27055A1 (de)
MX (1) MXPA04000917A (de)
MY (1) MY128464A (de)
NO (1) NO20040404L (de)
NZ (1) NZ530579A (de)
PA (1) PA8551601A1 (de)
PE (1) PE20030276A1 (de)
PL (1) PL366986A1 (de)
UA (1) UA77685C2 (de)
UY (1) UY27403A1 (de)
WO (1) WO2003011860A2 (de)
YU (1) YU2704A (de)
ZA (1) ZA200400652B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100398106C (zh) * 2001-04-23 2008-07-02 弗·哈夫曼-拉罗切有限公司 Nk-1受体拮抗剂对抗良性前列腺增生的用途
SE521512C2 (sv) * 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
EP3473251B1 (de) 2002-12-20 2023-12-13 NicoNovum AB Nikotin-cellulose-kombination
ATE366576T1 (de) * 2003-01-31 2007-08-15 Hoffmann La Roche Neue kristallmodifikation von 2-(3,5-bis- trifluormethyl-phenyl)-n-6-(1,1-dioxo-1lamda-6-
EP1776342B1 (de) 2004-07-06 2011-03-02 F. Hoffmann-La Roche AG Herstellungsverfahren für carboxamid-pyridin-derivate als zwischenprodukte bei der synthese von nk-1-rezeptor-antagonisten
JP4767973B2 (ja) * 2005-02-22 2011-09-07 エフ．ホフマン−ラ ロシュ アーゲー Ｎｋ１アンタゴニスト
AU2006218193A1 (en) 2005-02-25 2006-08-31 F. Hoffmann-La Roche Ag Tablets with improved drug substance dispersibility
CA2646942C (en) 2006-03-16 2014-07-29 Modoral Brands Inc. Improved snuff composition
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
US10383894B2 (en) * 2010-03-17 2019-08-20 Lutran Industries, Inc. Human medicinal treatment using salt of peroxymonosulfuric acid
AU2014347644B2 (en) 2013-11-08 2018-06-14 Kissei Pharmaceutical Co., Ltd. Carboxymethyl piperidine derivative
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
WO2016141341A1 (en) 2015-03-04 2016-09-09 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
WO2019236852A1 (en) * 2018-06-08 2019-12-12 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6435115A (en) * 1987-07-31 1989-02-06 Nippon Seiko Kk Bearing device
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
CA2178219C (en) 1993-12-29 2005-03-22 Raymond Baker Substituted morpholine derivatives and their use as therapeutic agents
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
DK1035115T3 (da) * 1999-02-24 2005-01-24 Hoffmann La Roche 4-phenylpyridinderivater og anvendelse deraf som NK-1-receptorantagonister
CN100398106C (zh) * 2001-04-23 2008-07-02 弗·哈夫曼-拉罗切有限公司 Nk-1受体拮抗剂对抗良性前列腺增生的用途

Also Published As

Publication number Publication date
EA006238B1 (ru) 2005-10-27
NZ530579A (en) 2006-02-24
CN1537025A (zh) 2004-10-13
HUP0400398A2 (hu) 2004-09-28
DE60232246D1 (de) 2009-06-18
JP2005500354A (ja) 2005-01-06
CA2452502C (en) 2011-02-15
UY27403A1 (es) 2003-04-30
ECSP044963A (es) 2004-03-23
EA200400109A1 (ru) 2004-08-26
YU2704A (sh) 2006-08-17
EP1414525A2 (de) 2004-05-06
PE20030276A1 (es) 2003-03-29
MXPA04000917A (es) 2004-04-02
BR0211523A (pt) 2004-09-14
EP1414525B1 (de) 2009-05-06
MY128464A (en) 2007-02-28
PA8551601A1 (es) 2003-06-30
WO2003011860A2 (en) 2003-02-13
WO2003011860A3 (en) 2003-09-04
HUP0400398A3 (en) 2010-06-28
JP4700908B2 (ja) 2011-06-15
ES2324209T3 (es) 2009-08-03
HRP20040039A2 (en) 2004-06-30
CN1289497C (zh) 2006-12-13
PL366986A1 (en) 2005-02-07
GT200200159A (es) 2003-05-16
KR100577101B1 (ko) 2006-05-10
MA27055A1 (fr) 2004-12-20
NO20040404L (no) 2004-01-29
AU2002355652B2 (en) 2007-07-05
UA77685C2 (en) 2007-01-15
KR20040029386A (ko) 2004-04-06
HK1069136A1 (en) 2005-05-13
US20030064983A1 (en) 2003-04-03
AR034921A1 (es) 2004-03-24
US6849624B2 (en) 2005-02-01
ZA200400652B (en) 2005-04-28
CA2452502A1 (en) 2003-02-13

Similar Documents

Publication Publication Date Title
BR0216099B1 (pt) "conjunto de desgaste".
EP1555267A4 (de) 2,3-DIHYDRO-6-NITROIMIDAZOç2,1-b]OXAZOLE
DE60314124D1 (de) 2-(2,6-dichlorphenyl)-diarylimidazole
DK2308855T3 (da) 2,4-Diaminopyrimidinderivater
NO20042474L (no) Reguleringsventil-stromningsjusteringsanordning.
IT1320120B1 (it) 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-0-tolil-piridin-3-il) -isobutirrammide.
ATE430600T1 (de) 2-(3,5-bis-trifluormethyl-phenyl)-n- 6-(1,1-dio o-1.lambda.6-thiomorpholin-4-yl)-4-(2-methyl- oder 4-fluor-2-methyl-substituiertes)phenyl-pyridin- - yl -n-methyl-isobutyramid
AR028357A1 (es) 4-bencil-1-[2-(4-hidroxi-fenoxi)-etil]-piperidin-3,4-diol
DE60129750D1 (de) Antiblend-, antibeschlagselement
DE60138903D1 (de) N-(1,2,4-triazoloazinyl)thiophensulfonamid-verbindungen als herbizide
NO20041455L (no) Zirkonium-/metalloksidfibrer.
DE60315471D1 (de) 2,5-disubstituierte 3-mercaptopentansaure
NO20030868D0 (no) N-(3,5-diklor-2-metoksyfenyl)-4-metoksy-3-piperazin-1-yl- benzensulfonamid
NO20042980L (no) 3,4-dihydro-1H-isokinolin-2-yl-derivater
ATE263165T1 (de) 3-(4,5-dihydroisoxazol-5-yl)benzoylpyrazole
ATE365725T1 (de) Biologisch aktive 4h-benzo 1,4öoxazin-3-one
DZ3441A1 (fr) Nouvelles phenylpiperazines.
ES1048400Y (es) Bota-patin mejorada.
DE60232170D1 (de) Thieno-(1,3)-oxazin-4-one mit lipase inhibierender wirkung
AR027974A1 (es) 1-aril-ciclopropilmetilamino-1,3,5-triazinas substituidas
ATE470655T1 (de) Substituierte 1,5-diaminopentan-3-ol-verbindungen
IS7131A (is) Nýjar 2,4-díamínóþíasól afleiður
DOP2001000274A (es) Inhibidores de espiropirimidin-2,4,6-triona metaloproteinasas
IS7299A (is) 3,4-díhýdró-1H-ísókínólóín-2-ýl-afleiður
ITRM20010151V0 (it) Macchina trincia-erba perfezionata.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1414525

Country of ref document: EP